The 5 most recent market catalysts affecting $MTNB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 65
Matinas BioPharma Board Approves 1-For-15 Reverse Stock Split Effective September 28, 2026
Matinas BioPharma's board approved a 1-for-15 reverse stock split, effective September 28, 2026, a move authorized by stockholders in June 2025. Reverse stock splits are typically …
Sep 4, 2026
Corporate Catalyst
Neutral
Impact 75
Matinas Biopharma Obtains NYSE Noncompliance Notice
The NYSE non-compliance notice for Matinas Biopharma (MTNB) is a significant negative catalyst. Such notices often indicate a failure to meet listing standards, typically related t…
Jul 27, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Monday's Pre-Market Session
This filing, generated by an automated content engine, simply reports pre-market price changes for a selection of health care stocks. It does not disclose any specific corporate ev…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 85
Matinas Biopharma Holdings shares are trading lower. The company announced it entered into a definitive purchase agreement to sell Matinas BioPharma Nanotechnologies, Inc., including MAT220 to Azurity Pharmaceuticals.
This headline represents a significant corporate catalyst for Matinas Biopharma. The sale of a subsidiary, especially one containing a key asset like MAT220, can be interpreted in …
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 95
Matinas BioPharma Strikes Merger Agreement With GH Power To Form New NYSE-Listed Entity GH Power International; Signs $4M Deal To Sell Its Matinas BioPharma Nanotechnologies To Azurity Pharmaceuticals
Matinas BioPharma (MTNB) is undergoing a significant transformation, effectively exiting the biopharma industry. The company is merging with GH Power to form a new NYSE-listed enti…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.